Nkarta

NKTX

시가총액 US$1.29억

Nkarta NASDAQ: NKTX said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety.

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: September 16, 2026 H.C.

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, today announced the appointment of Alyssa Levin to its Board of Directors, where she will also serve as Chair of the Audit Committee. The company has also strengthened its leadership team with two key additions. Clara Cambon-Thiebaud joins as Vice President, Regulatory Affairs, based in New York, and Céline Breda as Vice President, Chemistry Manufacturing and Controls (CMC). This leadership team expansion comes as Cyllene Tx advances its lead candidate, EG110A, towards late-stage clinical development for neurogenic bladder-related incontinence.

At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.

Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026 Cash balance of $266.7 million on March 31, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026.

Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.

SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol amendments are designed to alleviate the need for overnight stays and reduce the overall burden on patients, enabling outpatient administration of NKX019 – an investigational CAR-NK cell therapy – by community research centers and community rheumatologists.

SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference.

SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025.  “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience, right-sized our workforce to be a responsible steward of investor capital, and continued to advance our CAR-NK cell therapy platform through dose escalation in the clinic,” said Paul J. Hastings, Chief Executive Officer of Nkarta. “Thoughtfully leveraging our safety data, we are now dosing patients at 4 billion cells in a three-dose cycle for a total of 12 billion cells as we look to maximize the depth and durability of B-cell depletion and clinical response, positioning us to unlock the full potential of NKX019 for people living with autoimmune disease.”